Inspire Medical Systems, Inc.
NYSE:INSPMedical - Devices
+$0.51 today
- Market cap
- $1.68B
- Beta
- 0.73
- P/E (TTM)
- 9.1
- EPS (TTM)
- $4.57
Volume 0.51M
Average 1.13M
INSP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Inspire Medical Systems, Inc.NYSE: INSP
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin dips below year-ago levels
Q2 FY2026 selling, general & admin of $147.28M fell 7.7% year over year, behind the +7.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +24.9% a year.
Context
- Selling, general & admin amounted to 68.5% of revenue in FY2025, up 2.5 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 13 analysts of $636.63M (+1.9%) for the fiscal year ending Dec 2026, a slowdown from the +17.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $147.28M-3.2% QoQ
- Last fiscal yearDec 2025
- $624.64M+17.9% YoY
- LTMJun 2026
- $620.31M+7.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 624.64M USD
- Year-over-year change
- +17.9%
- 4-year CAGR
- +32.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 624.64M | +17.9% |
| FY2024 | 2024-12-31 | 529.61M | +17.2% |
| FY2023 | 2023-12-31 | 451.96M | +40.9% |
| FY2022 | 2022-12-31 | 320.69M | +58.3% |
| FY2021 | 2021-12-31 | 202.62M | — |
Selling, General & Admin vs competitors
How INSP compares with its peers on the latest reported figures
- INSP's LTM Jun 2026 selling, general & admin of $620.31M is the 2nd highest of the 9 companies compared; the peer median is $207.67M.
- Its year-over-year change of +7.7% is the 5th highest of 9, against a peer median of +8.7%.
- Selling, general & admin amounts to 69.0% of revenue for INSP, versus a peer median of 35.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $2.06B | -42.1% | -29.3% | 32.0% |
| LTM Jun 2026 | $620.31M | +7.7% | +24.9% | 69.0% | |
| LTM Jun 2026 | $312.81M | +10.0% | +12.3% | 21.2% | |
| LTM Mar 2026 | $238.7M | +27.6% | +37.1% | 74.1% | |
| LTM Mar 2026 | $220.91M | +7.5% | +10.6% | 48.2% | |
| LTM Jul 2026 | $194.42M | +13.3% | +1.1% | 10.6% | |
| LTM Sep 2026 | $130.43M | -67.2% | +1.6% | 4.4% | |
| LTM Jun 2026 | $106M | -7.8% | +1.9% | 90.6% | |
| LTM Mar 2026 | $98.35M | +13.1% | +16.1% | 38.4% | |
| Peer median (excluding INSP) | $207.67M | +8.7% | +6.2% | 35.2% | |
Competitors are the stored peer set for INSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 233.39M | 407.86M | 624.8M | 802.8M | 911.98M |
| Cost of Revenue | 33.28M | 66.12M | 96.58M | 122.99M | 133.23M |
| Gross Profit | 200.12M | 341.74M | 528.22M | 679.82M | 778.76M |
| Gross Margin | 85.7% | 83.8% | 84.5% | 84.7% | 85.4% |
| Research & Development | 37.35M | 68.65M | 116.54M | 114.13M | 103.17M |
| Selling, General & Admin | 202.62M | 320.69M | 451.96M | 529.61M | 624.64M |
| Operating Expenses | 239.97M | 389.33M | 568.49M | 643.74M | 727.8M |
| Depreciation & Amortization | 1.22M | 1.86M | 2.85M | 6.55M | 13.96M |
| EBITDA | (38.62M) | (40.73M) | (17.06M) | 65.03M | 79.79M |
| EBITDA Margin | -16.5% | -10.0% | -2.7% | 8.1% | 8.7% |
| Operating Income | (39.85M) | (47.59M) | (40.27M) | 36.08M | 50.95M |
| Operating Margin | -17.1% | -11.7% | -6.4% | 4.5% | 5.6% |
| Interest Income | 125K | 5.05M | 20.56M | 23.25M | 17.54M |
| Interest Expense | 2.13M | 1.68M | 0 | 22K | 137K |
| Other Income / Expenses | (2.12M) | 3.32M | 20.37M | 22.37M | 14.74M |
| Income Before Tax | (41.97M) | (44.27M) | (19.91M) | 58.45M | 65.7M |
| Pre-Tax Margin | -18.0% | -10.9% | -3.2% | 7.3% | 7.2% |
| Income Tax Expense | 72K | 613K | 1.25M | 4.94M | (79.73M) |
| Net Income | (42.04M) | (44.88M) | (21.15M) | 53.51M | 145.42M |
| Net Margin | -18.0% | -11.0% | -3.4% | 6.7% | 15.9% |
| EPS (Basic) | (1.54) | (1.60) | (0.72) | 1.80 | 4.95 |
| EPS (Diluted) | (1.54) | (1.60) | (0.72) | 1.75 | 4.89 |
| Weighted Avg Shares | 27.26M | 28.07M | 29.3M | 29.76M | 29.37M |
| Weighted Avg Shares (Diluted) | 27.26M | 28.07M | 29.3M | 30.54M | 29.76M |
Inspire Medical Systems, Inc.
NYSE:INSP
Intrinsic Alpha fair value
Locked
Current Price
$58.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.